PMID- 35425712
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220429
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - BAP1-Related ceRNA (NEAT1/miR-10a-5p/SERPINE1) Promotes Proliferation and 
      Migration of Kidney Cancer Cells.
PG  - 852515
LID - 10.3389/fonc.2022.852515 [doi]
LID - 852515
AB  - BACKGROUND: BAP1 is an important tumor suppressor involved in various biological 
      processes and is commonly lost or inactivated in clear-cell renal cell carcinoma 
      (ccRCC). However, the role of the BAP1-deficient tumor competing endogenous RNA 
      (ceRNA) network involved in ccRCC remains unclear. Thus, this study aims to 
      investigate the prognostic BAP1-related ceRNA in ccRCC. METHODS: Raw data was 
      obtained from the TCGA and the differentially expressed genes were screened to 
      establish a BAP1-related ceRNA network. Subsequently, the role of the ceRNA axis 
      was validated using phenotypic experiments. Dual-luciferase reporter assays and 
      fluorescence in situ hybridization (FISH) assays were used to confirm the ceRNA 
      network. RESULTS: Nuclear enriched abundant transcript 1 (NEAT1) expression was 
      significantly increased in kidney cancer cell lines. NEAT1 knockdown 
      significantly inhibited cell proliferation and migration, which could be reversed 
      by miR-10a-5p inhibitor. Dual-luciferase reporter assay confirmed miR-10a-5p as a 
      common target of NEAT1 and Serine protease inhibitor family E member 1 
      (SERPINE1). FISH assays revealed the co-localization of NEAT1 and miR-10a-5p in 
      the cytoplasm. Additionally, the methylation level of SERPINE1 in ccRCC was 
      significantly lower than that in normal tissues. Furthermore, SERPINE1 expression 
      was positively correlated with multiple immune cell infiltration levels. 
      CONCLUSIONS: In BAP1-deficient ccRCC, NEAT1 competitively binds to miR-10a-5p, 
      indirectly upregulating SERPINE1 expression to promote kidney cancer cell 
      proliferation. Furthermore, NEAT1/miR-10a-5p/SERPINE1 were found to be 
      independent prognostic factors of ccRCC.
CI  - Copyright (c) 2022 Liu, Xu, Li, Yu, Feng, Xu and Chen.
FAU - Liu, Rui-Ji
AU  - Liu RJ
AD  - Department of Urology, Affiliated Zhongda Hospital of Southeast University, 
      Nanjing, China.
AD  - Surgical Research Center, Institute of Urology, Southeast University Medical 
      School, Nanjing, China.
FAU - Xu, Zhi-Peng
AU  - Xu ZP
AD  - Department of Urology, Affiliated Zhongda Hospital of Southeast University, 
      Nanjing, China.
AD  - Surgical Research Center, Institute of Urology, Southeast University Medical 
      School, Nanjing, China.
FAU - Li, Shu-Ying
AU  - Li SY
AD  - Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Cancer Hospital 
      affiliate to School of Medicine, UESTC, Chengdu, China.
FAU - Yu, Jun-Jie
AU  - Yu JJ
AD  - Department of Urology, Affiliated Zhongda Hospital of Southeast University, 
      Nanjing, China.
AD  - Surgical Research Center, Institute of Urology, Southeast University Medical 
      School, Nanjing, China.
FAU - Feng, Ning-Han
AU  - Feng NH
AD  - Department of Urology, Wuxi No.2 People's Hospital of Nanjing Medical University, 
      Wuxi, China.
FAU - Xu, Bin
AU  - Xu B
AD  - Department of Urology, Affiliated Zhongda Hospital of Southeast University, 
      Nanjing, China.
AD  - Surgical Research Center, Institute of Urology, Southeast University Medical 
      School, Nanjing, China.
FAU - Chen, Ming
AU  - Chen M
AD  - Department of Urology, Affiliated Zhongda Hospital of Southeast University, 
      Nanjing, China.
AD  - Surgical Research Center, Institute of Urology, Southeast University Medical 
      School, Nanjing, China.
AD  - Nanjing Lishui District People's Hospital, Zhongda Hospital Lishui Branch, 
      Southeast University, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20220329
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9004599
OTO - NOTNLM
OT  - DNA methylation
OT  - ceRNA
OT  - clear-cell renal cell carcinoma
OT  - immune microenvironment
OT  - prognosis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/16 06:00
MHDA- 2022/04/16 06:01
PMCR- 2022/01/01
CRDT- 2022/04/15 05:31
PHST- 2022/01/11 00:00 [received]
PHST- 2022/02/25 00:00 [accepted]
PHST- 2022/04/15 05:31 [entrez]
PHST- 2022/04/16 06:00 [pubmed]
PHST- 2022/04/16 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.852515 [doi]
PST - epublish
SO  - Front Oncol. 2022 Mar 29;12:852515. doi: 10.3389/fonc.2022.852515. eCollection 
      2022.